FDA Considers 500 mg Subcutaneous Lecanemab Dose for Alzheimer’s, Study Shows Comparable Efficacy to IV Formulation

The U.S. Food and Drug Administration (FDA) is evaluating a 500 mg subcutaneous initiation dose of lecanemab (Leqembi, Eisai) for Alzheimer’s disease, following data from a study presented at the Alzheimer’s Association International Conference 2026. The research, led by Michael Irizarry, MD, MPH, senior vice president of clinical research at Eisai, found subcutaneous and intravenous (IV) formulations of the drug to be bioequivalent, with comparable safety and patient-reported convenience.

FDA Considers 500 mg Subcutaneous Dose for Lecanemab

The FDA has approved a subcutaneous 360 mg maintenance dose of lecanemab and is reviewing a 500 mg initiation dose, which aims to improve patient access and reduce the burden of frequent clinic visits. “With the IV initiation or maintenance dose, patients require an intravenous line and must visit an infusion center, which can be logistically challenging,” Irizarry told Healio. “Subcutaneous administration allows for home use after training, which is a significant advantage.”

The proposed 500 mg subcutaneous dose is part of a broader effort to expand treatment options. The Prescription Drug User Fee Act (PDUFA) date for the 500 mg initiation dose is August 24, 2026, according to the study.

Bioequivalence and Efficacy of Subcutaneous vs. IV Administration

A phase 3 substudy involving 613 patients with Alzheimer’s disease found that weekly 500 mg subcutaneous doses and biweekly 10 mg/kg IV doses were bioequivalent. Amyloid reduction, a key marker of treatment effectiveness, was consistent regardless of administration route, according to the research.

Exposure-response modeling further indicated that subcutaneous and IV formulations yielded similar clinical outcomes. “Exposure to the drug predicts both efficacy and the risk of adverse effects like amyloid-related imaging abnormalities (ARIA),” Irizarry explained. “The subcutaneous dose achieved the same therapeutic exposure as the IV formulation.”

Patients Report High Satisfaction With Subcutaneous Dosing

Overall, 97% of patients who transitioned from IV to subcutaneous lecanemab in a retrospective survey described their experience as “favorable” or “very favorable.” Key advantages included the speed of administration (10–15 seconds vs. 1 hour for IV), reduced invasiveness, and greater flexibility. “Patients preferred subcutaneous injection for its ease of use and ability to administer at home,” Irizarry noted.

Additional findings from the Clarity AD trial showed that 94% of patients felt confident in self-administering the subcutaneous dose, while 85% believed it would help them resume daily activities. Safety profiles were comparable, though systemic reactions were less common with subcutaneous injections (less than 2% vs. 26% with IV infusions).

Safety Profile and Adverse Reactions

No cases of ARIA-E, intracerebral hemorrhage, or hypersensitivity were linked to subcutaneous administration. “The safety profile was robust, with minimal immunogenicity concerns,” Irizarry said.

Patients with the APOE4 allele, a genetic risk factor for Alzheimer’s, also showed positive outcomes.

Real-World Impact and Future Outlook

The findings underscore the potential for subcutaneous lecanemab to become a preferred treatment option, particularly for patients who find IV infusions inconvenient. “Some patients value the in-person interaction during IV visits, while others prioritize home administration,” Irizarry said. “This flexibility could improve adherence and quality of life.”

However, clinicians must remain vigilant about adherence, as self-administration requires training and monitoring. “If patients struggle with dosing, we may need to revert to IV therapy,” Irizarry added. The FDA’s decision on the 500 mg subcutaneous dose is anticipated to provide clarity for healthcare providers and patients alike.

Key Takeaways

• The FDA is considering a 500 mg subcutaneous initiation dose of lecanemab for Alzheimer’s disease.
• Subcutaneous and IV formulations of lecanemab are bioequivalent, with comparable amyloid reduction and safety profiles.
• 97% of patients reported favorable experiences with subcutaneous dosing, citing convenience and ease of use.
• Subcutaneous administration reduces systemic reactions and eliminates the need for IV lines or clinic visits.
• The FDA’s PDUFA date for the 500 mg subcutaneous dose is August 24, 2026.